Advantagene, Inc. d.b.a. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/02/19	$22,500,000	Series C	H7 Holdings Level One Partners Northpond Ventures Sands Capital	undisclosed